Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

They synergy of industry, academic institutions and state agencies fosters innovation and strengthens Ireland’s ...